RxDoctor Payments Data

Erasme Coly, MD

Cardiovascular Disease · Johnson City, TNNPI 1083745335

Payments from drug & device makers

$7,397in general payments, 2019–2025

Across 217 payments — averaging $34.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$4K
  • Biotronik Inc.$1K
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$507
  • Novartis$496
  • Abbott$368
  • Johnson & Johnson$345
  • plus $1K from 14 others

What the payments were for

  • Travel & lodging$3,49147%
  • Food & beverage$3,74451%
  • Education$1622%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,397 in reported general payments places this provider in the 70th percentile of 429 cardiovascular disease providers in Tennessee.

See all cardiovascular disease providers in Tennessee

Medicare billing

Part B allowed, 2024
$444,144
Medicare patients
1,105
Services billed
4,430

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban763$643,767
XareltoRivaroxaban102$112,707
EntrestoSacubitril/Valsartan91$79,547
BrilintaTicagrelor111$73,649
JardianceEmpagliflozin37$31,038
FarxigaDapagliflozin Propanediol21$26,577
Repatha SureclickEvolocumab32$18,117
Ranolazine ErRanolazine94$9,993
Dabigatran EtexilateDabigatran Etexilate Mesylate22$4,769
Metoprolol Succinate542$4,747
Prasugrel Hcl19$3,881
Flecainide Acetate115$3,854
Diltiazem 24hr Er (Cd)Diltiazem Hcl92$3,230
Nebivolol Hcl30$2,995
Amiodarone Hcl98$2,637

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$148$643,767763 claims
Johnson & JohnsonXarelto$345$112,707102 claims
AstraZenecaBrilinta, Farxiga$205$100,226132 claims
NovartisEntresto$496$79,54791 claims
Boehringer IngelheimJardiance$200$31,03837 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 429 cardiovascular disease providers in Tennessee.

Other cardiovascular disease in Johnson City

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →